We performed in vitro experiments using a total of ten human PC cell lines to evaluate anti-tumor effect of AZD1775 (WEE1 inhibitor) alone or combination with AZD0156 (ATM inhibitor).
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.
Thus, we investigated the radiosensitizing efficacy of the novel drug combination of Wee1 and PARP1/2 inhibitors (AZD1775 and olaparib, respectively) in pancreatic cancer.